A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
收藏DataCite Commons2026-01-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008901/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine if the addition of apalutamide to ADT provides
superior efficacy in improving radiographic progression-free survival (rPFS) or overall
survival (OS) for participants with mHSPC.
提供机构：
Vivli
创建时间：
2023-04-19
